A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

NCT03018405 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia/Myelodysplastic Syndrome
Multiple Myeloma (MM)

Interventions

BIOLOGICAL: NKR-2 cells

Sponsor

Celyad Oncology SA